Crinetics Pharmaceuticals
CRNX
225 hedge funds and large institutions have $4.49B invested in Crinetics Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 86 increasing their positions, 73 reducing their positions, and 35 closing their positions.
416% more call options, than puts
Call options by funds: $45.9M | Put options by funds: $8.9M
49% more capital invested
Capital invested by funds: $3.01B → $4.49B (+$1.48B)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
18% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 73
17% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 35
2.69% more ownership
Funds ownership: 111.68% → 114.37% (+2.7%)
1% more funds holding
Funds holding: 222 → 225 (+3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$82.3M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$35.9M |
| 3 |
JP Morgan Chase
New York
|
+$29.6M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$14.3M |
| 5 |
RI
RTW Investments
New York
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$32.5M |
| 2 |
VPC
Vestal Point Capital
New York
|
-$24M |
| 3 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$21M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$20.1M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$12.3M |
CRNX Hedge Fund Activity: Q3 2025 in Review
225 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2025, worth a combined $4.49B — up 49% from $3.01B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CRNX positions and 35 closed out — a net gain of 6 holders — while 86 added to existing stakes and 73 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $82.3M. The largest seller was State Street, cutting an estimated $32.5M.
- 225 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2025, up from 222 in Q2 2025.
- Funds reported $4.49B of Crinetics Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
- 41 funds opened new Crinetics Pharmaceuticals positions in Q3 2025 and 35 closed out, a net change of +6 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $82.3M added.
- The largest Crinetics Pharmaceuticals seller in Q3 2025 was State Street, an estimated $32.5M sold.
Based on aggregated 13F filings for Q3 2025.